FDA Approves First Nasal Spray, Neffy, to Curb Anaphylaxis, An Alternative to Injections
By Ernie Mundell HealthDay Reporter
FRIDAY, Aug. 9, 2024 -- People who are nervous about administering a rescue shot for anaphylaxis finally have a new alternative in a nasal spray.
The U.S. Food and Drug Administration on Friday announced that it has approved neffy, the first non-injected treatment for life-threatening allergic reactions.
The epinephrine nasal spray is for use by adults and children who weigh more than 66 pounds, the agency said.
"Anaphylaxis is life-threatening and some people, particularly children, may delay or avoid treatment due to fear of injections,” Dr. Kelly Stone, associate director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluation and Research, said in an agency statement. “The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis. As a result, neffy provides an important treatment option and addresses an unmet need.”
People with allergies can experience a sudden, frightening reaction to allergens -- often certain foods, medications or insect stings.
Until now, epinephrine has been the only rescue medication when such incidents occur, and it's only been administered via a needle.
Neffy, made by ARS Pharmaceuticals, is delivered as a spray spritzed into one nostril, the FDA said. If the first dose doesn't ease symptoms, the agency urges giving a second dose (from a new dispenser) into the same nostril. Monitor patients closely after epinephrine is used, in case further treatment, including emergency medical help, is needed.
"Neffy’s approval is based on four studies in 175 healthy adults, without anaphylaxis, that measured the epinephrine concentrations in the blood following administration of neffy or approved epinephrine injection products," the FDA said. "Results from these studies showed comparable epinephrine blood concentrations between neffy and approved epinephrine injection products."
The studies also showed that neffy was effective in triggering the kinds of increases in blood pressure and heart rate that are crucial to treating anaphylaxis.
Neffy can come with side effects. These may include: throat irritation, tingling nose, headache, nasal discomfort, feeling jittery, tingling sensation, fatigue, tremor, runny nose, itchiness inside the nose (nasal pruritus), sneezing, abdominal pain, gum pain, numbness in the mouth, nasal congestion, dizziness, nausea and vomiting.
"Neffy comes with a warning that certain nasal conditions, such as nasal polyps or a history of nasal surgery, may affect absorption of neffy, and patients with these conditions should consult with a health care professional to consider use of an injectable epinephrine product," the FDA added. "Neffy also comes with warnings and precautions about use of epinephrine by people with certain coexisting conditions and allergic reactions associated with sulfite."
The new approval comes after an expert advisory panel supported neffy's use back in May of 2023. In September, the FDA held back on approval, asking for further study.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-12 09:15
Read more
- Vasomotor Symptoms During Menopause May Up Risk for Type 2 Diabetes
- Kids Still Find It Easy to Buy Flavored Vapes Online
- Childbirth Can Bring Worrying Medical Bills, Even With Insurance
- Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
- Skin Patch Could Monitor Your Blood Pressure
- Human Cell Atlas Will Be 'Google Maps' for Health Research
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions